# US 2026/0077012 A1 · Compositions and methods for diagnosis and treatment of neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077012 A1
- Document ID: US20260077012A1
- Status: Published application
- Kind: A1
- Application number: 19/319,462
- Filed: 2025-09-04
- Published: 2026-03-19
- Earliest claimed: 2019-01-09
- Applicants: Epitracker, Inc.
- Inventors: Stephanie VENN-WATSON
- Web page: https://patentgrep.com/patent/US20260077012A1

## CPC

- A61K 38/05: Dipeptides
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/221: with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/231: having one or two double bonds
- A61K 31/232: having three or more double bonds, e.g. etretinate
- A61K 31/24: having an amino or nitro group
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61P 3/12: for electrolyte homeostasis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions including small molecule biochemicals, and salts and derivatives thereof, and methods for detection, treatment or prophylaxis of neurodegenerative diseases are provided, including compositions and methods for detecting and treating conditions that contribute to neurodegenerative diseases, including peripheral and central inflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition and hyperglycemia.

## Claims

### Claim 1

A method of treatment er prophylaxis of a neurodegenerative disease selected from the group consisting of Alzheimer's disease, dementias, Parkinson's disease, prion disease, motor neuron diseases, Huntington's disease, spinocerebellar ataxia, and spinal muscular atrophy; for treatment of one or more conditions that are contributors to neurodegenerative disease, wherein the one or more conditions are selected from the group consisting of peripheral inflammation, central inflammation, neuroinflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition, hyperglycemia, Th1-type inflammation, Th2-type inflammation, T-cell dependent B cell proliferation, allergy, asthma, atherosclerosis, autoimmunity, chronic inflammation, chronic obstructive pulmonary disease (COPD), Crohn's disease, cutaneous responses to tissue damage, fibrosis, hematological oncology, a metabolic disease, organ transplantation, psoriasis, pulmonary fibrosis, a pulmonary response to respiratory infection, restenosis, rheumatoid arthritis, sarcoidosis, stromal biology in tumors, systemic lupus erythematosus (SLE), ulcerative colitis, and vascular inflammation; or for treatment of a neurodegenerative disease that is driven or exacerbated by one or more factors selected from the group consisting of alpha smooth muscle actin (αSMA), CD38, CD40, collagen I, collagen III, e-selectin, fibroblast proliferation, human leukocyte antigen-DR isotype (HLA-DR), immunoglobulin G, interferon gamma-induced protein 10 (IP-10/CXCL10), interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11), interleukin (IL)-6, IL-8 (CXCL8), IL-17A, macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase (MMP)-1, MMP-9, monocyte chemoattractant protein 1 (MCP-1), P selectin, plasminogen activation inhibitor 1 (PAI-1), prostaglandin E2 (PGE2), T cell proliferation, thrombomodulin, tissue factor, TIMP-1, tumor necrosis factor alpha (TNFα), vascular cell adhesion molecule (VCAM-1), and vascular endothelial growth factor 2 (VEGFR2), the method comprising:
administering to a patient in need thereof, an effective amount of one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more small molecule biochemicals is gamma-glutamylhistidine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more small molecule biochemicals is S-adenosylhomocysteine.

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering hippurate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the one or more conditions that are contributors to neurodegenerative disease is selected from the group consisting of chronic inflammation, neuroinflammation, and Alzheimer's disease.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein a serum, plasma, red blood cell, or tissue concentration of the one or more small molecule biochemicals, or the pharmaceutically acceptable salts, solvates, or esters thereof, is increased by from 1.1 to 6 times of the patient's baseline concentration and/or to a concentration greater than 0.5 μM and less than 30 μM.

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more small molecule biochemicals, or the pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof, is administered in a form selected from the group consisting of a foodstuff, a nutritional supplement, and a pharmaceutical composition in a unit dosage form.

### Claim 13 (depends on 8)

The method of claim 8, wherein the unit dosage form comprises from 0.01 mg to 10000 mg of the one or more small molecule biochemicals, or the pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein from 2.5 mg to 50 mg of the one or more small molecule biochemicals, or the pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof, is administered to the patient, per 1 kg of body weight, per day.

### Claim 15

A pharmaceutical composition for treatment of a neurodegenerative disease selected from the group consisting of Alzheimer's disease, dementias, Parkinson's disease, prion disease, motor neuron diseases, Huntington's disease, spinocerebellar ataxia, and spinal muscular atrophy; for treatment of one or more conditions that are contributors to neurodegenerative disease, wherein the one or more conditions are selected from the group consisting of peripheral and central inflammation, neuroinflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition, hyperglycemia, Th1-type inflammation, Th2-type inflammation, T-cell dependent B cell proliferation, allergy, asthma, atherosclerosis, autoimmunity, chronic inflammation, chronic obstructive pulmonary disease (COPD), Crohn's disease, cutaneous responses to tissue damage, fibrosis, hematological oncology, metabolic diseases, organ transplantation, psoriasis, pulmonary fibrosis, pulmonary responses to respiratory infections, restenosis, rheumatoid arthritis, sarcoidosis, stromal biology in tumors, systemic lupus erythematosus (SLE), ulcerative colitis, and vascular inflammation; or for treatment of a neurodegenerative disease that is driven or exacerbated by one or more factors selected from the group consisting of alpha smooth muscle actin (αSMA), CD38, CD40, collagen I, collagen III, e-selectin, fibroblast proliferation, human leukocyte antigen-DR isotype (HLA-DR), immunoglobulin G, interferon gamma-induced protein 10 (IP-10/CXCL10), interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11), interleukin (IL)-6, IL-8 (CXCL8), IL-17A, macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase (MMP)-1, MMP-9, monocyte chemoattractant protein 1 (MCP-1), P selectin, plasminogen activation inhibitor 1 (PAI-1), prostaglandin E2 (PGE2), T cell proliferation, thrombomodulin, tissue factor, TIMP-1, tumor necrosis factor alpha (TNFα), vascular cell adhesion molecule (VCAM-1), and vascular endothelial growth factor 2 (VEGFR2), the pharmaceutical composition comprising:
one or more small molecule biochemicals selected from the group consisting of 4-guanidinobutanoate, gamma-glutamylhistidine, S-adenosylhomocysteine, or combinations thereof; or pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof; and
a pharmaceutically acceptable carrier.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 15)

The pharmaceutical composition of claim 15, wherein the pharmaceutical composition further comprises hippurate.

### Claim 20

(canceled)

### Claim 21

A method of modulating levels of biomarkers in a subject, said biomarkers selected from the group consisting of MCP-1, CD38+, T cell proliferation, secreted IgG, sIL-17A, TNF-alpha, VCAM-1, Collagen III, CXCL10, CXCL11, fibroblast proliferation, and TIMP-1, the method comprising:
administering to a patient in need thereof, an effective amount of one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or pharmaceutically acceptable salts, solvates, or esters thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein a serum, plasma, red blood cell, or tissue concentration of the one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or the pharmaceutically acceptable salts, solvates, or esters thereof, is increased by from 1.1 to 6 times of the patient's baseline concentration and/or to a concentration greater than 0.5 μM and less than 30 μM.

### Claim 23 (depends on 21)

The method of claim 21, wherein the one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or pharmaceutically acceptable salts, solvates, or esters thereof, is administered in a form selected from the group consisting of a foodstuff, a nutritional supplement, and a pharmaceutical composition in a unit dosage form.

### Claim 24 (depends on 23)

The method of claim 23, wherein the unit dosage form comprises from 0.01 mg to 10000 mg of the one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or pharmaceutically acceptable salts, solvates, or esters thereof.

### Claim 25 (depends on 21)

The method of claim 21, wherein from 2.5 mg to 50 mg of the one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or pharmaceutically acceptable salts, solvates, or esters thereof is administered to the patient, per 1 kg of body weight, per day.

### Claim 26 (depends on 21)

The method of claim 21, further comprising administering to a patient in need thereof, an effective amount of hippurate.

### Claim 27 (depends on 26)

The method of claim 26, wherein from 2.5 mg to 50 mg of the one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or pharmaceutically acceptable salts, solvates, or esters thereof, is administered to the patient, per 1 kg of body weight, per day.

### Claim 28 (depends on 26)

The method of claim 26, wherein a serum, plasma, red blood cell, or tissue concentration of the one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof or hippurate; or pharmaceutically acceptable salts, solvates, or esters thereof, is increased by from 1.1 to 6 times of the patient's baseline concentration and/or to a concentration greater than 0.5 μM and less than 30 μM.

### Claim 29 (depends on 21)

The method of claim 21, wherein a serum, plasma, red blood cell, or tissue concentration of the one or more small molecule biochemicals selected from the group consisting of gamma-glutamylhistidine, S-adenosylhomocysteine, or a combination thereof; or the pharmaceutically acceptable salts, solvates, or esters thereof, is increased by from 1.1 to 6 times of the patient's baseline concentration and/or to a concentration greater than 0.5 μM and less than 30 μM.
